The South African Medical Research Council interviewed Professor Andreas Diacon, founder and CEO at TASK Applied Science, on the future of TB treatment. TASK performs clinical trials in TB and has been a partner in the PanACEA consortium since the first EDCTP granting phase.
New and improved drugs are necessary to increase the effectivity of treatment of TB, Professor Diacon explains, but improvement of diagnostics and development of vaccines are essential as well to eradicate the disease. Such a multi faceted strategy requires a concentrated effort of many players globally. Specific to the African context he argues that the scientific agenda should yield a robust and cost effective overall strategy.
You can watch the interview here: